Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of ORMD-0801 in T2DM with Inadequate Glycemic Control
NCT04754334Phase 3Terminated
- Sponsor
- Oramed Pharmaceuticals Inc.
- Start
- Mar 2021
- Primary completion
- Jan 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of ORMD-0801 in type 2 diabetes mellitus (T2DM), sponsored by Oramed Pharmaceuticals Inc.. Started Mar 2021; status: terminated.
02
Drugs
ORMD-0801
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04754334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04754334.